# Early Intervention in COVID-19: Favipiravir Verses Standard Care

> **NCT04373733** · PHASE3 · COMPLETED · sponsor: **Chelsea and Westminster NHS Foundation Trust** · enrollment: 502 (actual)

## Conditions studied

- Coronavirus Infection

## Interventions

- **DRUG:** Favipiravir
- **OTHER:** Standard of care management

## Key facts

- **NCT ID:** NCT04373733
- **Lead sponsor:** Chelsea and Westminster NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-01
- **Primary completion:** 2021-06-25
- **Final completion:** 2021-06-25
- **Target enrollment:** 502 (ACTUAL)
- **Last updated:** 2021-11-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04373733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04373733, "Early Intervention in COVID-19: Favipiravir Verses Standard Care". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04373733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*